These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31804006)

  • 1. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.
    Sakhdari A; Thakral B; Loghavi S; Kanagal-Shamanna R; Yin CC; Zuo Z; Routbort MJ; Luthra R; Medeiros LJ; Wang SA; Patel KP; Ok CY
    Cancer Med; 2020 Feb; 9(3):849-858. PubMed ID: 31804006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
    J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
    Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
    Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
    Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
    Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
    Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
    Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
    Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
    Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
    Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    Thomas DA; O'Brien S; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Ravandi F; Verstovsek S; Jorgensen JL; Bueso-Ramos C; Andreeff M; Pierce S; Garris R; Keating MJ; Cortes J; Kantarjian HM
    J Clin Oncol; 2010 Aug; 28(24):3880-9. PubMed ID: 20660823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
    Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma.
    Tian XP; Su N; Wang L; Huang WJ; Liu YH; Zhang X; Huang HQ; Lin TY; Ma SY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sun C; Sang W; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Hai L; Li GW; Song LY; Kang TB; Xie D; Cai QQ
    Clin Cancer Res; 2020 Jul; 26(14):3760-3770. PubMed ID: 32234760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.
    Liang DC; Chen SH; Liu HC; Yang CP; Yeh TC; Jaing TH; Hung IJ; Hou JY; Lin TH; Lin CH; Shih LY
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28853218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Othman T; Moskoff BN; Ho G; Tenold ME; Azenkot T; Krackeler ML; Fisch SC; Potter LA; Kaesberg PR; Welborn JL; Wun T; Esteghamat NS; Hoeg RT; Rosenberg AS; Abedi M; Tuscano JM; Jonas BA
    Leuk Res; 2022 Aug; 119():106885. PubMed ID: 35738024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.